| Literature DB >> 32219023 |
Josefin Hagström1, Malin Ander1, Martin Cernvall1, Brjánn Ljótsson2, Henrik W Wiman1, Louise von Essen1, Joanne Woodford1.
Abstract
BACKGROUND: A subgroup of adolescent and young adult (AYA) survivors of cancer during adolescence report high levels of psychological distress. To date, evidence-based psychological interventions tailored to the cancer-related concerns experienced by this population are lacking. The present study aimed to (1) examine the feasibility and preliminary efficacy of an individualized cognitive behavioral therapy (CBT) intervention for AYA survivors of cancer during adolescence; and (2) identify and conceptualize cancer-related concerns as well as maintaining factors using cognitive-behavioral theory.Entities:
Keywords: AYA survivor; Behavioral conceptualization; CBT; Cancer; Feasibility; Internet-based intervention; Psychological concerns
Year: 2020 PMID: 32219023 PMCID: PMC7085902 DOI: 10.7717/peerj.8714
Source DB: PubMed Journal: PeerJ ISSN: 2167-8359 Impact factor: 2.984
Number of participants receiving the respective CBT-based treatment techniques in treatment.
| Functional analysis | 10 |
| Goal setting | 10 |
| Psychoeducation including experiential exercises | 10 |
| Setting a maintenance plan | 9 |
| Exploring values | 8 |
| Self-monitoring | 8 |
| Mindfulness-based exercises | 7 |
| Value-guided behavior change/exposure relating to social avoidance and fear of failure | 6 |
| Worry time, worry exposure, problem-solving | 5 |
| Behavioral activation | 3 |
| General affect exposure | 3 |
| Stress management techniques | 3 |
| Emotion regulation/distress tolerance training | 2 |
| Exposure (interoceptive exposure and exposure & response prevention) | 2 |
| Interpersonal effectiveness skills training | 2 |
| Relaxation exercises | 1 |
Participant characteristics (n = 10).
| Age at study-start (years) | 21 | 2.9 | 17–25 |
| Age at cancer diagnosis (years) | 15.9 | 1.4 | 13–17 |
| Time since end of cancer treatment (years) ( | 3.2 | 1.7 | 1–6 |
| Female/Male | 4/6 | ||
| Cancer diagnosis from self-report | |||
| Leukemia | 4 | ||
| CNS-tumor | 2 | ||
| Lymphoma | 2 | ||
| Soft tissue sarcoma | 1 | ||
| Other malignancy | 1 | ||
| Cancer diagnosis from registry | |||
| Leukemia | 5 | ||
| CNS-tumor | 2 | ||
| Lymphoma | 2 | ||
| Soft tissue sarcoma | 1 | ||
| Other malignancy | 0 | ||
| History of relapse yes/no | 1/9 | ||
| Living situation | |||
| With parents | 6 | ||
| Not with parents | 4 | ||
| Relationship status | |||
| Single | 5 | ||
| In a relationship | 5 | ||
| Employment status | |||
| Student | 6 | ||
| Employed full-time | 1 | ||
| Employed part-time | 2 | ||
| Unemployed | 1 | ||
| Sick leave | 0 | ||
| Self-reported late effects yes | 8/2 | ||
| Previous psychological treatment yes/no | 6/4 |
Notes.
number of participants
Standard Deviation
Self-reported late effects included anemia, balance problems, fatigue/tiredness, headaches, high blood pressure, kidney stone, loss of appetite, memory problems, nausea, nerve damage, nerve pain, numbness, speech difficulties, and thrombus.
Means, standard deviations, and ranges for the clinical outcome measurements at baseline, post-treatment, and three month follow-up assessment (n = 10).
| MADRS-S | 17.0 | 6.2 (8–27) | 10.9 | 7.6 (3–26) | 9.8 | 7.1 (3–25) |
| BAI | 14.6 | 16.5 (1–56) | 7.9 | 6.5 (2–21) | 6.1 | 8.0 (0–25) |
| PCL-C | 37.0 | 14.2 (20–70) | 27.1 | 8.1 (20–45) | 27.4 | 11.7 (18–55) |
| PSWQ | 48.9 | 11.5 (32–63) | 40.9 | 5.7 (32–49) | 38.8 | 9.3 (22.4–52) |
| AAQ-II | 36.3 | 10.6 (23–55) | 32.4 | 10.3 (19–47) | 28.6 | 12.1 (17–50) |
| BIS | 13.2 | 7.9 (5–29) | 8.0 | 4.1 (4–14) | 8.8 | 8.1 (0–25) |
| FAS | 26.8 | 5.6 (20–36) | 22.3 | 5.5 (17–31) | 21.5 | 5.6 (12–29) |
| PHQ-15 | 9.5 | 6.7 (2–23) | 6.1 | 3.6 (1–12) | 6.8 | 4.1 (2–14) |
| R-RSQ | 53.0 | 14.1 (30–72) | 47.8 | 17.5 (25–74) | 44.0 | 15.2 (24–70) |
| SDS | 12.9 | 5.9 (4–21) | 7.5 | 6.1 (0–15) | 5.8 | 5.5 (0–15) |
| SHAI Main | 14.8 | 4.6 (8–20) | 11.7 | 4.6 (4–17) | 8.0 | 3.2 (1–12) |
| SHAI Negative consequences | 3.4 | 2.7 (0–7) | 2.3 | 2.2 (1–6) | 2.9 | 1.9 (0–5) |
| SHAI-Avoidance | 14.0 | 14.3 (0–42) | 8.1 | 9.6 (0–22) | 7.6 | 8.2 (0–19) |
| SHAI Reassurance | 15.1 | 6.6 (6–24) | 11.9 | 9.3 (1–23) | 7.3 | 6.1 (0–17) |
Notes.
n =8.
number of participants
Standard Deviation
Montgomery Åsberg Depression Rating Scale –Self Assessment
Beck Anxiety Inventory
The PTSD Checklist-Civilian Version
Penn State Worry Questionnaire
Acceptance and Action Questionnaire-II
Body Image Scale
Fatigue Assessment Scale
Public Health Questionnaire-15
Rumination Scale of the Response Style Questionnaire
Sheehan Disability Scale
The Short Health Anxiety Inventory
Number of individuals with complete data reaching reliable change from baseline to post-assessment and from baseline to follow-up assessment (n = 7).
| MADRS-S | 2 | 3 |
| PCL-C | 2 | 2 |
| BAI | 1 | 1 |
| BAI, PCL-C and/or MADRS-S | 3 | 4 |
Notes.
number of participants
Montgomery Åsberg Depression Rating Scale–Self Assessment
The PTSD Checklist-Civilian Version
Beck Anxiety Inventory
Reliable change scores were 7.7 for MADRS-S, 13.6 for PCL-C, and 22.9 for BAI.
Summary of feasibility outcomes.
| Recruitment | |
| Number identified via the Swedish Childhood Registry | |
| Number of potential participants | |
| Number contacted via telephone | |
| Number contacted via post | |
| Number of non-participating | |
| By exclusion | |
| Declined participation | |
| Lost to recruitment | |
| Number assessed for eligibility | |
| Number found ineligible | |
| Number meeting inclusion criteria | |
| Number included in the study | |
| Reasons for non-participation | |
| Declined participation | |
| No need for support | |
| Online non-consent | |
| Unable to travel to study sites | |
| No interest prior to information given | |
| No interest after receiving information | |
| In counselling | |
| Low trust in psychotherapy | |
| No reason given | |
| No perceived cancer | |
| Intellectual disabilities | |
| Feeling anger | |
| Moved | |
| Lack of time | |
| Lost to recruitment | |
| No contact | |
| Administrative failure | |
| No address identified | |
| By exclusion | |
| In psychological treatment | |
| Age | |
| In assessment for psychological treatment | |
| Deceased | |
| Unable to travel to study sites | |
| Participation too burdensome | |
| Attrition | 10% |
| Percentage dropping out of the study | 10% |
| Percentage dropping out of the treatment | |
| Data collection | Post-treatment, 70% |
| Percentage completing assessments | 3-month follow-up, 80% |
| Numbers of missing items | |
| Treatment delivery | Mean = 12.6, range = 7–15 |
| Number of treatment sessions | Mean = 25, range = 18–36 |
| Length of treatment (weeks) | |
| Number of early treatment terminations | |
| Number of cancelled treatment sessions | Mean = 3.4, range = 0–11 |
Figure 1Adapted CONSORT diagram illustrating the flow of participants through the study.
Figure 2Identified precipitatory and current cancer-related concerns and maintaining factors.
Figure 3Identified precipitatory and current cancer-related concerns and maintaining factors.